INmune Bio (INMB) has an ongoing Phase I/II trial in men with metastatic castration-resistant prostate cancer. The Company announced the participation of a patient at the West Los Angeles VA Medical Center in the trial. The participant received the investigational intervention, as an out-patient per the protocol, under the care of Matthew Rettig, MD., Chief, Hematology-Oncology, VA Greater Los Angeles Healthcare System, Professor of Medicine and Urology, Medical Director Prostate Cancer Program, David Geffen School of Medicine and the Jonsson Comprehensive Cancer Center at the UCLA. The Veteran received the “medium” dose of INKmune initiating the Phase II portion of the trial.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio initiated with a Buy at Rodman & Renshaw
- Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks
- INmune Bio treatment of epidermolysis bullosa receives FDA orphan designation
- Inmune Bio Announces Stock Options and Leadership Changes
- INmune Bio, OmniScience announce partnership to accelerate Alzheimer’s trial